Hyderabad, Aug. 29
Suven Life Sciences Ltd announced on Tuesday that it has signed an agreement with the US pharma major Eli Lilly & Company to collaborate on pre-clinical research of molecules in the therapeutic area of central nervous system (CNS) disorders.
In a press release here, the Suven Vice-President, Drug Discovery, Dr Ramakrishna Nirogi, said, "This effort is a collaboration between Suven and Lilly, with scientists from both parties working together in a team, with the goal of identifying potent, oral compounds that selectively modulate the specified G-Protein Coupled Receptor for the target CNS disease."
In terms of the deal, Suven would receive payments from Lilly and potentially downstream payments if the identified candidates were selected by Lilly for further pre-clinical research and development.
The Suven Vice-Chairman and CEO, Mr Venkat Jasti, termed this as the company's first true research collaboration with a global pharmaceutical company. He expects this to help the company realise the next step of its vision.
With the in-house capabilities and drug discovery and development support services expertise, Suven has generated a diverse pipeline of drug candidates in CNS that are in various phases of pre-clinical development, the release said.